Acute myelogenous leukemia (AML) is characterized by the accumulation of immature cells due to disturbed differentiation and proliferation of the myeloid lineage. Genetic alterations affecting transcription factors and receptor tyrosine kinases have been identified in AML and causally linked to the disease. The goal of this review is to address the role of the different genetic alterations in self-renewal and proliferation and to discuss the cellular background in which these events occur during the pathogenesis of AML. Data from AML samples, clinical studies and mouse models for AML will be used to support the different theories regarding the leukemogenesis of AML. Finally, this review wants to highlight the implication of these findings for the therapy of AML.
Introduction
Although 'nonsolid' and 'solid' tumors have been traditionally viewed separately in terms of their biology, behavior and pathogenesis, accumulating evidence gathered from clinical and experimental hematology suggests that many of the concepts developed for epithelial tumors may indeed be applicable to hematological malignancies and vice versa. This includes the idea that multiple genetic events are required to transform a cell (for a review see Fearon and Vogelstein 1 ), the concept that tumorigenesis is initiated by disruption of a tissuespecific 'gatekeeper' pathway 2 and the notion that tumors derive from a stem cell. This review argues that the disruption of the gatekeeper signaling pathways imparts a selective growth advantage by increasing self-renewal, allowing the expansion of a clonal cell pool, in which secondary genetic alterations accumulate and result in tumor growth.
Genetic alterations in AML

Hematopoiesis and the bad seed
Insight into the pathways that are disrupted in acute myelogenous leukemia (AML) has basically come from three different approaches: cytogenetic identification and molecular cloning of recurrent chromosomal rearrangements, identification of retroviral integration sites in murine models of AML and screening for mutations in genes known to be important regulators of hematopoiesis. 3 Importantly, the results from these different approaches have revealed a general underlying theme. The genetic alterations in AML often affect transcription factors that also have an important role in normal hematopoiesis 4 (see Table 1 and Figure 1 ). Although oncogenes (like receptor tyrosine kinases (RTK)) and classical tumor-suppressor genes (like RB and p53) are also mutated in AML, experimental evidence suggests that the hematopoiesis-specific transcription factors are the gatekeepers of AML. The transcription factors disrupted in AML can be classified into three different groups: (1) lineage-specific transcription factors, which play pivotal roles in the differentiation process of a specific lineages (eg the CAAT/ enhancer binding factor alpha (C/EBPa), a key regulator of granulopoiesis; the ETS transcription factor Pu.1, which is instrumental in determining cell fate into the myeloid lineage; the zinc-finger transcription factor Gata-1, an important regulator of erythro-and megakaryopoiesis; and the retinoic acid receptor alpha (RARA) (see Figure 1) ; (2) transcription factors that are expressed in multiple lineages, and which are probably more aptly designated as transcriptional organizers (eg the core binding factor (CBF) family, and the C2H2 zinc-finger transcription factor Evi-1); and (3) transcription factors that are generally thought to orchestrate global changes in transcriptional control during tissue development (eg homeobox proteins, such as the HOX genes). However, as is often the case when one attempts to confine biological entities to specific functions, this simple classification is slowly breaking down. For instance, recent studies predict that the lineage-specific transcription factors may also have pivotal functions in multipotent cells 5 and that factors that regulate multiple lineages may have nonredundant functions in specific lineages 6 ( Figure 1 ).
Tumor suppressor or proto-oncogene?
Genes that are altered in tumorigenesis have normally been classified as either proto-oncogenes or tumor suppressors. Are the transcription factors involved in AML tumor suppressor genes or oncogenes? Sporadic mutations in oncogenes result in the constitutive activation of the gene, whereas mutations in tumor-suppressor genes reduce or inactivate gene/protein function. Tumor-suppressor genes are also associated with familiar cancer syndromes where the first copy of the gene is mutated in the germ line while the second copy is often inactivated by deletion of the gene (Knudson's hypothesis). Are the transcription factors involved in AML tumor-suppressor genes or oncogenes? At least two of the transcription factors (namely RUNX1 and CEBPA) have been found mutated in families with a predisposition to AML. 7, 8 Interestingly, only in one affected family member that developed an AML, a mutation in the second allele of CEBPA was identified while the other two affected family members showed a remaining wild-type (wt) allele in the AML cells. 7 A similar observation was made for 
Figure 1
Transcription factors important in normal hematopoiesis and AML.
RUNX1.
8 Since these are rare syndromes with small numbers of patients, the results should be interpreted with caution.
HOX and EVI-1: typical oncogenes
Mutations affecting the HOX and EVI-1 genes appear to be activating events, making them classical proto-oncogenes. Activation of one of several HOX genes can either occur through direct disruption of the gene (eg in translocations involving the NUP98 gene) or indirectly by genetic disruption of the MLL gene, which encodes a chromatin modeling protein important for regulating HOX expression 9 . Animal models have demonstrated that the fusion protein, as well as the wt HOX gene affected, can induce an AML when overexpressed in bone marrow cells. Interestingly, the latency of AML induced by MLL and HOX genes in mouse models is relatively short correlating well with clinical observations (for a review see Owens and Hawley 10 ). Similarly, several genetic alterations in AML have been described that lead to the constitutive expression of Evi-1 (for a review see Buonamici et al 11 ) , and again animal models have demonstrated that their expression induces myelodysplastic syndrome (MDS)/AML or myeloid blast crisis of chronic myeloid leukemia (CML) when expressed in cooperation with BCR/ABL. [12] [13] [14] PU.1 and RARA: typical tumor suppressors?
Mutations in the PU.1 gene are relatively rare and primarily associated with myelomonocytic (M4) or undifferentiated (M0) AML. 15, [16] [17] [18] In all cases studied, mutations affecting PU.1 appear to be inactivating or null mutations. However, inactivation of PU.1 is exclusively monoallelic and because no evidence of a dominant-negative (DN) function could be discerned, haploinsufficiency might be the molecular mechanism. 15 Interestingly, mice are hypomorphic for PU.1, but neither PU.1
À/À mice develop AML, suggesting that some remaining activity of Pu.1 is required probably to initiate lineage commitment. 19 The most common translocation in APL fuses the RARA on chromosome 17 to the PML gene on chromosome 15, leading to a PML/RARA fusion protein (accounting for 495% of cases). In the remaining cases of APL, the RARA gene is fused to other genes like PLZF, NPM, NuMA and STAT5, arguing for a common molecular mechanism involving the disruption of the RARA pathway. Thus, RARA would also appear to be acting as a tumor suppressor, its inactivation inhibiting cell death associated with normal granulocytic differentiation. Indeed, gene translocations may simultaneously provide two 'hits'. 20 
CBF: tumor suppressor and oncogene?
CBF is a heterodimeric transcription factor composed of an alpha subunit, encoded by one of three RUNX genes, and a unique beta subunit (CBFb). 21 In most cases, and consistent with a tumor-suppressor function, the functional integrity of the transcription factor is altered or impaired by the generation of a fusion protein (via chromosomal translocations or inversions) which acts DN (for details of the CBF leukemia translocations see Figure 2 ). Mouse models have been pivotal in confirming this hypothesis by demonstrating that the fusion proteins act in a DN fashion to disrupt normal CBF function in embryonic hematopoiesis (Supplementary Information is available at the Leukemia website, see Supplementary Table 1) . [22] [23] [24] [25] Additionally, point mutations and/or deletions in the RUNX1 gene have been found in AML, segregating with the rare familial platelet disorder with predisposition to AML (FPD/AML) 8 or occurring in AML with no or little differentiation (FAB-M0) (for a review see Osato 26 ). These mutations can be divided into two types: (1) null mutations that completely disrupt protein expression or lead to expression of a truncated protein with probably neither wt nor DN activity or (2) DN mutations that either disrupt DNA-binding activity but do not impair interaction with transcriptional coregulators (Runt domain mutations), or, more rarely, retain DNA-binding activity but have lost strong transactivation ability (C-terminal mutations). Different types of RUNX1 mutations can be activating or inactivating and further studies are needed to investigate their molecular mechanisms.
CEBPA and GATA-1: tumor suppressor turned oncogene?
C/EBPa belongs to a family of leucine zipper transcription factors and was shown to have an important role in white-fat adipogenesis and granulocytic differentiation. 27, 28 Monoallelic and biallelic mutations in the gene encoding C/EBPa (CEBPA) have been identified in AML. Monoallelic mutations clustering in the N-terminal coding region of CEBPA lead to the preferential use of a downstream ATG, resulting in an N-terminally truncated DN 30 kDa protein. 29 Retroviral expression of the 30 kDa C/EBPa protein was shown to block differentiation Figure 2 Translocation and associated fusion proteins involving core-binding factors (CBF).
Gatekeeper pathways and cellular background J Cammenga of primary human but not murine hematopoietic cells, demonstrating a DN but also species-specific effect. 30 Heterodimerization of the mutant protein with wt C/EBPa has not been shown, leaving the molecular mechanism elusive. Loss of the N-terminal domain disrupts interaction and repression of E2F, thereby preventing C/EBPa directed growth arrest induced by downregulation of myc, that accompanies terminal differentiation 31 (for a review see McKnight   32 ). In contrast the N-terminal truncated C/EBPa protein does not lose its ability to induce lineage commitment (for a review see Nerlov 33 ). About 50% of patients carrying N-terminal mutations in C/EBPa also harbor C-terminal point mutations in the basic leucine zipper region of the second allele. [34] [35] [36] If the 30 kDa C/EBPa protein is DN, why is the other C/EBPa copy also inactivated? If C/EBPa is a classical tumor suppressor, why do only 50% of the samples show biallelic mutations, and why are none of these mutations complete inactivating mutations? A recent paper identified germline mutations in the CEBPA gene in a familial AML syndrome, creating an N-terminal truncated C/EBPa protein identical to the one observed in sporadic AML. 7 If this N-terminal truncated protein (p30) is DN how can it occur in the germ line (the CEBPA À/À mice die shortly after birth and have no mature granulocytes!)? Mutations in the transcription factor GATA-1 have been identified in transient myeloproliferative disorder (TMD) and acute megakaryocytic leukemia (AMKL) in newborn children with Down syndrome. 37 These mutations also result in the expression of a truncated Gata-1 missing the N-terminus. The specificity of the GATA-1, PU.1 and CEBPA mutations suggests that diminished but not complete loss of function is required for AML pathogenesis.
Gatekeepers in AML
The concept of 'gatekeepers' was first established in studies of colon cancer, where inactivation of a specific gatekeeper pathway is the first genetic alteration in tumorigenesis. 2 Although several gatekeepers have been identified in specific tumor types, other tumors are also thought to have distinct gatekeeper pathways that are awaiting discovery. 38 Is there evidence that the hematopoiesis-specific transcription factors have a 'gatekeeper'-function in AML? Several lines of evidence suggest that the genetic alterations affecting the hematopoietic transcription factors are probably the initiating event, establishing a preleukemic clone, but requiring secondary events for disease penetration. Unfortunately, the identification of a premalignant clone in AML is rarely observed, making it difficult to prove the theory of gatekeepers in AML. MDS is known to precede AML, and their association with RUNX1 mutations is strong evidence that these mutations may be an initiating event in AML (for a review see Osato 26 ). Additionally, cytogenetic and genetic abnormalities identified in therapy-related MDS (t-MDS) and AML (t-AML) have contributed to the concept that specific alterations involving transcription factors are the initiating genetic events in leukemogenesis. 39 Studies linking RUNX1 and CEBPA mutations to hereditary AML syndromes and the observation of concordant AML induction in identical twin pairs, which share the initiating clone carrying the same translocation affecting the MLL gene, do also support the idea of gatekeepers in AML (for a review see Greaves and Wiemels 40 ). Finally, animal models, in which the genetic disruptions have been mimicked, have clearly demonstrated that these events contribute to leukemogenesis, but secondary genetic events are required to shorten disease latency and increase penetrance (Supplementary Information is available at the Leukemia website, see Supplementary Table 1) .
Role of gatekeepers in AML
The molecular mechanism of the initial growth advantage resulting from the loss of the gatekeeper has never been clearly defined. It has been postulated that in AML the pool of leukemic cells is fed by an undifferentiated stem/progenitor cell and this concept has been extended recently to solid tumors (see also section on the target cell). While the disruption of specific gatekeepers in AML results only in a mild block in hematopoietic differentiation, more importantly it leads to an increased selfrenewal capacity. The increased self-renewal capacity results in an expansion of the premalignant cell clone while preventing loss of the clone to differentiation. What is the evidence for this function of gatekeepers in AML? An increase in progenitor numbers was observed in most models affecting RUNX1 arguing for an expansion of a preleukemic clone, but no overt leukemia was observed.
6,41-45 Absence of C/EBPa and decrease in Pu.1 expression also increase the number of hematopoietic progenitor cells probably by enhancing self-renewal (see section on the Target cell). 5, 46, 47 Mutations in the FLT3 gene are commonly found in AML but never identified in patients with myeloproliferative disease (see also below). Expression of mutant Flt3 in murine bone marrow leads to myeloproliferation at the expense of self-renewal, which would explain why the MPD induced by FLT3-internal tandem duplications (ITD) is not transplantable. 48 Early activation of the Flt3 receptor would probably lead to the loss of the malignant clone to differentiation, making it impossible to occur by itself. Coexpression of AML1/ETO and TEL/PDGFR leads to a transplantable AML, while the receptor tyrosine kinase fusion protein by itself only induces a nontransplantable myeloproliferative disease arguing again for a role of AML1/ETO in maintaining self-renewal capacity and the requirement of this function in the pathogenesis of AML. 49 Similar observations about the requirement of gatekeeper inactivation prior to the proliferative signal have been made in epithelial tumors. KRAS2 mutations in the colonic epithelial cells can lead to self-limiting hyperplastic lesions that do not progress to cancer. 50, 51 Only if these cells have acquired a mutation in the gatekeeper APC prior to the KRAS2 mutation a tumor will occur (for a review see Vogelstein and Kinzler 38 ). The APC gene is involved in the Wnt pathway which has an important role in hematopoietic stem cell self-renewal and also in the self-renewal of other stem cells 52 (for a review see Nelson and Nusse 53 ). Maybe the primary effect of the loss of gatekeeper function in all malignancies is to increase the self-renewal capacity to prevent differentiation and thereby the loss of the malignant clone induced by the subsequently acquired proliferative signals.
Secondary events in the pathogenesis of AML
Bone marrow from patients in remission and even from healthy volunteers show the presence of oncogenic fusion proteins arguing for secondary events in leukemia. 54, 55 Long latencies and low penetrance have also been observed in most mouse models of AML arguing for the requirement of additional genetic alterations (Supplementary Information is available at the Leukemia website, see Supplementary Table 1 ).
The usual suspects
Activation of the Ras pathway and mutations in RTK, leading to their constitutive activation, have been identified in combination with different leukemic fusion proteins. 56 ITD and mutations in the tyrosine kinase domain (TKD) of the FLT3 receptor are the most common. [57] [58] [59] Mutations of other RTK, for example KIT, have been identified in a small percentage of AML and are specifically associated with genetic alterations affecting members of the CBF family. 60, 61 These observations have led to a theory that at least two different pathways have to be affected in AML. 62 One pathway involves the activation of a tyrosine kinase (eg KIT, FLT3 or another yet unidentified RTK) leading to increased proliferation, cytokine independence and decreased apoptosis. The other pathway was implicated in blocking the differentiation of the cell. 62 Animal models have provided clear evidence for the causal role of the leukemia fusion genes in AML pathogenesis and their cooperation with other genetic alterations. Three different approaches have been used to shorten disease latency and increase penetrance in mouse models for AML (Supplementary Information is available at the Leukemia website, see Supplementary 48, 49, 66 or an antiapoptotic signal such as BCL- 2 67 ), or inactivation of a tumor-suppressor gene (eg ICSBP). 42 
Two-step leukemogenesis of AML, an oversimplification?
It has to be noticed that almost all models of myeloproliferative disease expressing activated receptor tyrosine kinases using retroviral vectors have utilized BALB/c mice. This mouse strain carries a mutation within the CDKN2A locus, leading to a decrease in the ability of the p16 INK4A protein to inhibit Rb phosphorylation, but leaves the p19 ARF protein unaffected. 68 Loss of p16 Ink4a is essential for macrophage immortalization and is shown to increase the clonal expansion of hematopoietic progenitor cells. 69, 70 When constitutively active tyrosine kinases are expressed in the bone marrow of BALB/c, they induce nontransplantable MPD, while in the B6/C3H or C57B/6 background a lymphoid malignancy is induced. 48, 66 Interestingly, the p16
INK4a negative background of the BALB/c mice is not needed to induce AML when PML/RARA is expressed with FLT3-ITD. 66 AML1/ETO was shown to downregulate p14 ARF directly. 71 Granulocytic sarcomas that develop in the conditional AML1/ETO knockin mice showed persistent p16
INK4a and p19 ARF expression. 43 As a result of the conflicting data on the role of p14 ARF in the pathogenesis of AML the p16 INK4a and p19 ARF À/À mice will be a valuable tool to study these questions.
The target cell
Two models of AML pathogenesis
Hematopoiesis is a hierarchical process starting with the longterm repopulating stem cell (HSC) that further differentiates via the multipotential progenitor (MPP) cell into the common myeloid progenitor (CMP) and the common lymphoid progenitor (CLP). The lineage restricted CMP cell gives rise to the granulocyte/macrophage progenitor (GMP), which then terminally differentiates into mature granulocytes and macrophages/ monocytes. 72, 73 Two competing theories exist on which cell acquires the genetic alteration in AML (see Figure 3 ):
(1) The stem cell model: The genetic alterations occur in the hematopoietic stem cell, which already has the ability for self-renewal, expresses the enzyme telomerase and is quiescent and hardly affected by chemotherapeutic drugs. (2) The (instructive and noninstructive) progenitor model: The genetic alteration occurs in a multipotent (instructive) or lineage-restricted progenitor cell (noninstructive) that regains, probably due to an altered transcriptional program, the ability for self-renewal.
Evidence for the stem cell model in AML
It is now widely accepted that AML arises from genetic alterations in the hematopoietic stem/progenitor cells and a number of excellent reviews have summarized the scientific evidence from animal models and clinical data to support this theory. [74] [75] [76] When Bonnet et al 77 enriched for CD34 þ /CD38À cells from AML samples, they were able to induce a leukemia in NOD/SCID mice with much fewer cells, arguing that the leukemic stem cell has very similar properties like the hematopoietic stem cell (HSC). 77 Lessard and Sauvageau 78 and Clarke et al 79 have shown the requirement of a gene called BMI-1 for the proliferative capacity of normal and leukemic stem cells. When Hoxa9 and Meis were expressed in normal or BMI-1À/À bone marrow they induced AML in both genetic backgrounds with similar phenotype, latency and penetrance. Interestingly, the Bmi-1 deficient mice showed much lower numbers of leukemic blasts in the peripheral blood and this phenotype could be rescued with the expression of Bmi-1. When the AML (induced by Hoxa9 and Meis1) was transplanted into secondary recipients, the normal cells induced leukemia while Bmi-1À/À cells failed to induce AML. 78 Additionally, mouse models of AML have shown that the fusion proteins have to be expressed early in hematopoietic differentiation to cause an AML (see Supplementary Figure 1 and Table 1 ).
Other evidence that the affected cell in AML might be a stem cell comes from analysis of patient samples. The RUNX1/ETO fusion protein was detected in B-lymphocytes and normal stem/ progenitor from patients with an AML harboring the t(8;21). 80 Leukemic fusion proteins are also detected in patients with AML in long-term remission, arguing for the occurrence of the genetic alteration in a hematopoietic stem cell. 54, 55 Recently, retroviral expression of AML1/ETO in human cord blood or peripheral blood progenitor cells (PBPC) showed stem cell expansion and long-term in vitro growth with extensive proliferation on stroma and in liquid culture. 44, 45 These cells could be differentiated to B lymphocytes and also transplanted with low efficiency into NOD/SCID mice arguing for the maintenance of a stem/MPP cell. 44 Evidence for the progenitor model Combined evidence from mouse models for APL using differentiation stage-specific promoters and transplantation of APL samples into NOD/SCID mice has led to the theory that a committed progenitor is the target of the translocation. This theory has been the subject of a recent review 76 The MLL-Gas7 translocation induced a mixed lineage leukemia (MLL) when the fusion protein was expressed in MPPs whereas it only induced a lymphoid or myeloid malignancy when expressed in either a CLP or CMP, which would argue in favor of the progenitor model. 81 Similarly, phenotypically identical AML was obtained when the MLL-ENL fusion protein was expressed selectively in either hematopoietic stem cells, CMPs or GMPs, also arguing in favor of the progenitor model. 82 Genes involved in the (acquired) self-renewal capacity of leukemic progenitor cells It has been proposed that the transforming genetic alterations occur in multipotential or lineage-restricted progenitor cells that will (due to the genetic alteration) acquire properties of a hematopoietic stem cell (like self-renewal). Some genes have been linked to these new properties of the leukemic progenitor cell and will be discussed in this section.
BMI-1: Two groups have shown that Bmi-1 is required for normal and leukemic stem cells maintenance, but the effect on the acquired self-renewal of progenitor cells was not evaluated.
HOX genes: Expression of the MLL-ENL fusion protein in either hematopoietic stem cells, CMP or GMP gave rise to the same disease (see above). 82 Hoxa9 and Hoxa7 are upregulated in the CMP and GMP expressing the MLL-ENL fusion protein and required for the transformation. 82, 83 Interestingly, the MLL-GAS7 fusion protein was able to transform hematopoietic cells in the absence of HoxA9 and HoxA7. 82, 84 WNT pathway: Recently, b-catenin was identified as being expressed at higher levels in progenitor cells from patients with blast crisis of CML than in normal progenitor cells. The CML progenitors formed self-renewing colonies and forced expression of axin (a b-catenin antagonist) partially reversed this effect, demonstrating a direct correlation between b-catenin and selfrenewal. 85 Previously, the Wnt pathway (to which b-catenin belongs) has been linked to stem cell renewal and functions probably through the activation of the HoxB4 protein that was shown to expand the stem cell pool when overexpressed in human and murine stem cells. 52, [86] [87] [88] Using oligonucleotide arrays, g-catenin (also called plakoglobin) was recently identified as a target of different leukemic fusion proteins and overexpression of the gene led to an AML. 89, 90 Unfortunately, most of the identified genes linked to the acquired self-renewal of the leukemic progenitor cells are also involved in normal stem cell self-renewal, which makes their potential use for the therapy of AML questionable.
Therapy
The gatekeepers
Besides a better understanding of the molecular mechanisms, does the identification of genetic alterations as gatekeepers in Figure 3 Three models of AML pathogenesis involving different hematopoietic cells.
Gatekeeper pathways and cellular background J Cammenga AML have an implication for the therapy of AML? As gatekeepers do have a specific role in the self-renewal of cancer progenitor/stem cells, restoring gatekeeper function should lead to the loss of the malignant clone by inducing differentiation and apoptosis. What is the clinical evidence for this hypothesis? APL is the only AML where we can restore the gatekeeper function due to the cloning and characterization of the PML/RARA fusion protein and the molecular mechanisms underlying the response to all-trans retinoic acid (ATRA) therapy. 91, 92 The good prognosis of APL is surprising because of the fact that a high percentage of the patients with APL have an activating mutation in the FLT3 receptor which is normally associated with a bad prognosis in AML. Obviously, this does not apply to APL when treated with ATRA and chemotherapy, which could be explained by the model shown in Figure 4 .
The target cell
Owing to knowledge obtained from animal models and studying patient samples, it is now widely accepted that the acute promyelocytic leukemia originates from a hematopoietic progenitor cell 77, [93] [94] [95] (for a review see Grimwade and Enver 76 ). Is the 5-year survival of treated APL much higher than for other subtypes of AML because with ATRA we do have a very specific, nontoxic substance that directly affects the altered gatekeeper or is it because the affected cell is a committed progenitor cell that is eradicated by the therapy? Probably it is a combination of these two facts.
Conclusions
Transcription factors important in normal hematopoiesis are affected in AML and probably function as gatekeepers in this disease. Disruption of the gatekeeper function mainly increases self-renewal capacity and prevents loss of the clone induced by subsequent acquired proliferative signals. Ablation of the gatekeeper function impairs granulocytic differentiation to variable degrees depending on the type of transcription factor involved. Loss of a lineage-specific transcription factor affects differentiation probably more than alterations of a transcriptional organizer. Secondary genetic alterations are required to induce AML and probably enhance the block in differentiation. The target cells in which these mutations occur may dictate the type and number of mutations required for the development of AML. The genetic alterations and the cell in which these events occur influence the outcome of the therapy, and because of their role in self-renewal, maintenance and initiation of AML cells, gatekeepers should be the preferential target for therapy.
What needs to be done?
(1) Identification of novel gatekeepers and their functional role in the pathogenesis of AML. Nonrandom chromosomal rearrangements are identified in approximately 50% of AML and are more common in young patients and in general associated with good prognosis (like t8;21, inv16, t15;17). The absence of chromosomal abnormalities especially in older patients with AML is associated with bad prognosis Figure 4 Model for the role of gatekeepers in the pathogenesis and therapy of AML.
Gatekeeper pathways and cellular background J Cammenga and genetic alterations are probably on the subchromosomal level (like mutations, silencing, etc). Unfortunately, the identification of new gatekeepers in AML might be very challenging.
96
(2) Better mouse models for AML are needed to test the role of gatekeepers and cellular background for the pathogenesis and therapy of AML. (3) Identification of target genes of transcription factors involved in AML in the correct cellular background. 97 We have come a long way developing adequate mouse models for AML and studying patient samples and thereby increasing our understanding of the molecular pathogenesis of this disease, so hopefully at the end of this endeavor, we will develop curative therapies for every patient with this devastating disease.
